

mapping cancer risk among individuals with a migration background across Europe

Nienke (C.J.) Alberts

D. Georges, Dr. A. Gini, Dr. I. Man, Dr. F. Bray, Dr. I. Baussano - International Agency for Research on Cancer, Lyon;
 Dr. S. Rosso, Dr. E. Migliore, Prof. Dr. L. Richiardi - University of Turin - Piedmont Cancer Registry;
 Dr. J. Galceran, Dr. M. Carulla - Cancer registry of Tarragona, Reus, Spain;
 Dr. A Bordoni, Dr. L. Ortelli - Cancer Registry of canton Ticino, Switzerland;
 Dr. M.D. Chirlaque López, Dr. A. Sánchez Gil - Cancer registry of Murcia, Spain;
 Dr. K. Van Herck, Dr. F. Verdoodt - Belgian Cancer Registry, Brussels, Belgium;
 Dr. O. Visser - Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands;

Dr. J. Didkowska and Dr. U Wojciechowska - Polish National Cancer Registry, Poland













No conflict of interest











- Data is not collected in a systematic way
- Harmonization of this data across countries/ registries is challenging









The lack of evidence and data has hindered the development of policies and programmes to achieve the SDGs (26) for migrants, refugees and other displaced populations. It has also limited progress towards the objectives of the Global Compact for Safe, Orderly and Regular Migration (GCM) (27), the Global Compact on Refugees (28,29) and the WHO Global action plan on promoting the health of refugees and migrants, 2019–2030 (30).



map cancer risk among migrants across

Europe Objectives



<u>Preparation phase:</u> Co-created a protocol to systematically collect cancer data stratified by birth country.



Objective 1: Collect real-world data to quantify cancer risk among migrants



Objective 2: Estimate the expected and preventable burden of cancer cases among migrants.



Objective 3: Assess the resources needed to scale up cancer elimination strategies for migrant populations.









map cancer risk among migrants across

Europe Objectives

Where we are now



<u>Preparation phase:</u> Co-created a protocol to systematically collect cancer data stratified by birth country.


- Involved 7 pilot registries



Objective 1: Collect real-world data to quantify cancer risk among migrants

Availability of data in EU

Pilot registry data results



Objective 2: Estimate the expected and preventable burden of cancer cases among migrants.



Objective 3: Assess the resources needed to scale up cancer elimination strategies for migrant populations.









Protocol for data collection



Cancer RADAR:

assess the current risk and preventable burden of cancer among individuals with a migration background across Europe

version October 2024












cancer.radar@iarc.who.in

1




What data will be





What data will be






What data will be









What is a 'migrant'?

Birth-country of a person:

- ✓ Often routinely collected for administrative purposes
- ✓ Objective and an unchanging attribute
- ✓ Birth-country refers to first-generation migrant
- ✓ Birth-country a proxy for ethnicity











Objectives

Where we are now



Preparation phase: Develop protocol to systematically collect cancer data stratified by birth country.


- Involved 7 pilot registries



Objective 1: Collect real-world data to quantify cancer risk among migrants

- Availability of data in EU

- Pilot registry data results



Objective 2: Estimate the expected and preventable burden of cancer cases among migrants.



Objective 3: Assess the resources needed to scale up cancer elimination strategies for migrant populations.









Availability and feasibility of data

- Survey was sent to 104 cancer collection
- Received responses from 77% (79/104) cancer registries across Europe
- 69% registries representing 20 countries expressed a positive intention to participate: 60% have data in-house and 9% need to retrieve

Reasons to share data

- Sufficient time
- Important
- Important to do this together within a network
- Aligns with other initiatives

Barriers to share data

- Limited staff capacity to collect and clean the data
- No budget
- Data sharing/retrieval is complex
- Potential high cost of data linkage and retrieval










Pilot data across 4 registries in Europe: breast and cervical cancer as an example



Grouped by ASIR in birth country:


Cervical cancer ASIR categories:

▲ High = >22

◆ Intermediate-high = 14-22

 \blacksquare Intermediate-low = 8.1-13

▼ Low = ≤8



Breast cancer ASIR categories:

♣ High = >65


◆ Intermediate-high = 46-65


 \blacksquare Intermediate-low = 31.1-46

♥ Low **=** ≤31

> ASIR = age-standardized incidence rate

Pilot data across 4 registries in Europe





Registries

Dashed-line represents the ASIR in the host population:


- ASIR for breast cancer (as we know) is high
- ASIR for cervical cancer in host pop. is close to the WHO elimination threshold of 4 / 100.000 py
- Incidence in host population
 Observed incidence in host country
- ▲ High
- Intermediate-high
- Intermediate-low
- ∇ Low


Theoretical incidence based on birth country

- ▲ High
- ♦ Intermediate-high
- Intermediate-low
- ∇ Low

ASIR = age-standardized incidence rate

Pilot data across 4 registries in Europe





Registries

Dashed-line represents the ASIR in the host population:

- ASIR for breast cancer (as we know) is high
- ASIR for cervical cancer in host pop. is close to the WHO elimination threshold of 4 / 100.000 py

The theoretical ASIR compared to the observed ASIR is:

- higher for cervical cancer
- lower/similar for breast cancer
- i.e. the risk in migrant population converges towards the risk in the host


- Incidence in host population
 Observed incidence in host country
- ▲ High
- Intermediate-high
- Intermediate-low
- ∇ Low


Theoretical incidence based on birth country

- ▲ High
- Intermediate-high
- Intermediate-low
- ∇ Low

ASIR = age-standardized incidence rate

Pilot data across 4 registries in Europe Intermediate-high





Intermediate-nign
Intermediate-low

▼ Low

-Migrants have a significantly higher ASIR for **cervical cancer** compared to the host population.

-For **breast cancer**, migrants have a similar or lower ASIR compared to the host population.


ASIR in a migrant's birth country is a good proxy for their ASIR in the host country. This pattern does not hold for breast cancer.

Pilot data across 4 registries in Europe:




What proportion of migrants have a lower (green), similar (blue), or higher (orange/red) ASIR when compared to the host population?

Pilot data across 4 registries in Europe:



- For most cancer types, migrants tend to have a similar (blue) or lower (green) ASIR when compared to the host population.

Pilot data across 4 registries in Europe:




- For most cancer types, migrants tend to have a similar (blue) or lower (green) ASIR when compared to the host population.
- For infection-related cancers, the ASIR is often higher (orange/red) among migrants than in the host population.



Pilot data across 4 registries in Europe

We can draw three conclusions from the data processing:

- Data are available locally at the highest possible level of detail.
- Analyses can be conducted in a decentralized manner, safeguarding small cell counts and ensuring anonymity.
- Coordinated international analyses enable more meaningful conclusions than those possible from individual countries or registries alone.











Protocol



Impact

- Improve the health of migrants
- Characterize knowledge gaps to increase awareness
- Inform public health decision making and stakeholder's actions
- Make the data openly accessible to help induce policy change
- Use the infrastructure and the lessons-learned in Europe, expand data collection to other regions in the world
- Note: We must be aware that this data and findings can be interpreted differently according to different sets of values. Our goal is to communicate the results of this work to promote equity-focused policymaking.





















C.J. Alberts



D. Georges



S. Rosso



F. Bray

Cancer RADAR working group:

D. Georges, Dr. A. Gini, Dr. I. Man, Dr. F. Bray, Dr. I. Baussano - International Agency for Research on Cancer, Lyon; Dr. S. Rosso, Dr. E. Migliore, Prof. Dr. L. Richiardi - University of Turin - Piedmont Cancer Registry; Dr. J. Galceran, Dr. M. Carulla - Cancer registry of Tarragona, Reus, Spain; Dr. A Bordoni, Dr. L. Ortelli - Cancer Registry of canton Ticino, Switzerland; Dr. M.D. Chirlaque López, Dr. A. Sánchez Gil - Cancer registry of Murcia, Spain; Dr. K. Van Herck, Dr. F. Verdoodt - Belgian Cancer Registry, Brussels, Belgium; Dr. O. Visser - Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands; Dr. J. Didkowska and Dr. U Wojciechowska -





DECISION MODELING CENTER













Methodology – stratified by birth-



Stomach (C16)



Liver (C22.0)



Numerator

Denominator

Cervix uteri (C53)



Breast (C50)



Colorectal (C18-20)



Lung (C33-34)

Cancer_ risk



Population-at-risk



All cancers (C00-97/C44)

Data collection



Step 1 - Data collection:

- by 5-year age groups
- by CI5 collection periods (2013-2017, 2008-2012, 1003-2007)



Step 2 - Data processing:

- highly-aggregated estimates i.e. anonymous data



Step 3 - Data sharing





PIR = Proportional incidence ratio Source: P Boyle, D.M. Parkin, Ch11, IARC, 1995